Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T for CNS B-cell ALL
NCT03064269Phase 1Recruiting
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.
- Start
- Mar 2017
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19 CAR-T cells in acute lymphoblastic leukemia (ALL), sponsored by Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd. Primary endpoint: Complete Remission Rate at 12 months. Started Mar 2017; status: recruiting.
02
Drugs
CD19 CAR-T cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03064269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03064269.